These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35047286)

  • 1. Severe Hypophosphatemia Following Ferric Carboxymaltose in a Patient With Inflammatory Bowel Disease.
    Ali A; Elmdaah A; Mustafa AM; Kumaravel Kanagavelu AS; Mohamed N; Sayed S
    Cureus; 2021 Dec; 13(12):e20452. PubMed ID: 35047286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interventions for treating iron deficiency anaemia in inflammatory bowel disease.
    Gordon M; Sinopoulou V; Iheozor-Ejiofor Z; Iqbal T; Allen P; Hoque S; Engineer J; Akobeng AK
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013529. PubMed ID: 33471939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypophosphataemia after ferric carboxymaltose is unrelated to symptoms, intestinal inflammation or vitamin D status.
    Fang W; Kenny R; Rizvi QU; McMahon LP; Garg M
    BMC Gastroenterol; 2020 Jun; 20(1):183. PubMed ID: 32522150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rare case of parental iron-induced persistent hypophosphatemia.
    Sullivan A; Lanham T; Rubin A
    J Community Hosp Intern Med Perspect; 2020 May; 10(2):166-167. PubMed ID: 32850057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
    JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Minimal Optimal Dose of Intravenous Ferric Carboxymaltose for Treatment of Iron Deficiency Anemia and Risk of Transient Hyperferritinemia.
    Alharbi AA; Alharbi AA; Bashen DS; Owaidah T
    J Blood Med; 2022; 13():681-690. PubMed ID: 36419736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
    Pollock RF; Muduma G
    Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
    Lyseng-Williamson KA; Keating GM
    Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    World J Gastroenterol; 2021 May; 27(17):2039-2053. PubMed ID: 34007138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hypophosphatemia following the administration of intravenous iron formulations: A case report and literature review].
    Lecoq AL; Dong C; Carbonnel F; Becquemont L
    Therapie; 2021; 76(6):705-714. PubMed ID: 33962799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose.
    Sobrado CW; Cançado RD; Sobrado LF; Frugis MO; Sobrado MF
    Arq Gastroenterol; 2015 Dec; 52(4):255-9. PubMed ID: 26840464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose.
    Fang W; McMahon LP; Bloom S; Garg M
    JGH Open; 2019 Oct; 3(5):438-440. PubMed ID: 31633052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractory hypophosphatemia following ferric carboxymaltose administration.
    Efe O; García JDC; Mount DB; Sheridan AM
    CEN Case Rep; 2021 Nov; 10(4):473-475. PubMed ID: 33715107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of intravenous iron-induced hypophosphatemia.
    Wolf M; Chertow GM; Macdougall IC; Kaper R; Krop J; Strauss W
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea.
    Lim EA; Sohn HS; Lee H; Choi SE
    Cost Eff Resour Alloc; 2014; 12():19. PubMed ID: 25278814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome.
    Glaspy JA; Wolf M; Strauss WE
    Adv Ther; 2021 Jul; 38(7):3531-3549. PubMed ID: 34053011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ferric carboxymaltose: a review of its use in iron deficiency.
    Keating GM
    Drugs; 2015 Jan; 75(1):101-27. PubMed ID: 25428711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypophosphatemia Is Common After Intravenous Ferric Carboxymaltose Infusion Among Patients With Symptomatic Heart Failure With Reduced Ejection Fraction.
    Dashwood A; Vale C; Laher S; Chui F; Hay K; Wong YW
    J Clin Pharmacol; 2021 Apr; 61(4):515-521. PubMed ID: 33051909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory bowel disease and anemia: intravenous iron treatment.
    Kangaspunta M; Haapamäki J; Färkkilä M; Arkkila P
    Scand J Gastroenterol; 2018 Apr; 53(4):430-434. PubMed ID: 29468908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.